Librarian View
LEADER
04462cam a22005415i 4500
001
12494228
005
20200728064610.0
006
m o d
007
cr nn 008mamaa
008
150613s2015 gw | o |||| 0|eng d
020
|a
9783319141510
|9
978-3-319-14151-0
024
7
|a
10.1007/978-3-319-14151-0
|2
doi
035
|a
(DE-He213)978-3-319-14151-0
035
|a
12494228
050
4
|a
RC261-271
072
7
|a
MJCL
|2
bicssc
072
7
|a
MED062000
|2
bisacsh
082
0
4
|a
614.5999
|2
23
245
0
0
|a
PARP Inhibitors for Cancer Therapy
|h
[electronic resource] /
|c
edited by Nicola J. Curtin, Ricky A. Sharma.
264
1
|a
Cham :
|b
Springer International Publishing :
|b
Imprint: Humana Press,
|c
2015.
300
|a
XIX, 591 p. 108 illus., 85 illus. in color :
|b
online resource.
336
|a
text
|b
txt
|2
rdacontent
337
|a
computer
|b
c
|2
rdamedia
338
|a
online resource
|b
cr
|2
rdacarrier
347
|a
text file
|b
PDF
|2
rda
490
1
|a
Cancer Drug Discovery and Development,
|x
2196-9906 ;
|v
83
505
0
|a
History of the discovery of poly (ADP-ribose) -- Discovery of the PARP superfamily and focus on the lesser exhibited but not lesser talented members -- The role of PARPs in DNA Strand Break Repair -- TIPs: Tankyrase Interacting Proteins -- PARP and Carcinogenesis -- Multitasking roles for poly(ADP-ribosyl)ation in aging and longevity -- Overview of PARP Inhibitor Design and Optimization -- Structure Based Design of PARP Inhibitors -- Preclinical chemosensitization by PARP inhibitors -- Classification of PARP inhibitors based on PARP trapping and catalytic inhibition, and rationale for combinations with topoisomerase I inhibitors and alkylating agents -- Radiosensitisation by poly(ADP-ribose) polymerase inhibition -- The vasoactivity of PARP inhibitors -- Synthetic lethality with Homologous Recombination Repair defects -- Targeting tumour hypoxia with PARP Inhibitors: Contextual synthetic lethality -- Other determinants of sensitivity -- Synthetic sickness with molecularly targeted agents against the EGFR pathway -- Disruption of DNA repair by cell cycle and transcriptional CDK inhibition -- Resistance to PARP Inhibitors Mediated by Secondary BRCA1/2 Mutations -- PARP inhibitor resistance - what is beyond BRCA1 or BRCA2 restoration -- Introduction to PARPi clinical trials and future directions -- Clinical trials investigating PARP inhibitors as single agents -- Clinical trials of PARP inhibitors with chemotherapy -- Combination of PARP inhibitors with clinical radiotherapy -- Biomarkers for PARP Inhibitors.
506
|a
Access restricted by licensing agreement.
520
|a
PARP Inhibitors for Cancer Therapy provides a comprehensive overview of the role of PARP—poly ADP ribose polymerase—in cancer therapy. The volume covers the history of the discovery of PARP and its role in DNA repair. Additionally, it describes the discovery of the PARP family, and includes a discussion of other DNA maintenance-associated PARPs. As well, the volume features a section on the accessible chemistry behind the development of inhibitors. PARP inhibitors—PARPi—are a group of pharmacological inhibitors that are particularly good targets for cancer therapy. PARP plays a pivotal role in DNA repair and may contribute to the therapeutic resistance to DNA-damaging agents used to treat cancer. Researchers have learned a great deal about the biology of PARP and how tumor-specific defects in DNA repair can be exploited by PARPi. The “synthetic lethality” of PARPi is an exciting concept for cancer therapy, and has led to heightened activity in this area.
590
|a
Access is available to the Yale community.
650
0
|a
Medicine.
650
0
|a
Oncology.
650
0
|a
Drug interactions.
700
1
|a
Curtin, Nicola J.
700
1
|a
Sharma, Ricky A.
710
2
|a
SpringerLink (Online service)
730
0
|a
Springer ebooks.
773
0
|t
Springer eBooks
776
0
8
|i
Printed edition:
|z
9783319141503
830
0
|a
Cancer drug discovery and development ;
|v
83.
852
8
0
|z
Online Resource
856
4
0
|y
Online book
|u
https://yale.idm.oclc.org/login?URL=http://dx.doi.org/10.1007/978-3-319-14151-0
901
|a
RC261-271
902
|a
Yale Internet Resource
|b
Yale Internet Resource >> None|DELIM|12633297
905
|a
online resource
907
|a
2015-07-06T13:43:20.000Z
946
|a
DO NOT EDIT. DO NOT EXPORT.
953
4
0
|a
http://dx.doi.org/10.1007/978-3-319-14151-0